With shares of AOL (NYSE:AOL) trading around $39, is AOL an OUTPERFORM, WAIT AND SEE or STAY AWAY? Let�� analyze the stock with the relevant sections of our CHEAT SHEET investing framework:
T = Trends for a Stock’s Movement
AOL�is a global Web services company with a range of brands and offerings that intrigue a global audience. The company’s business spans online content, products and services, which it offers to consumers, publishers and advertisers. Its business operations are focused on AOL Properties and Third Party Network.�It offers a range of display advertising, including text and banner advertising, mobile, video and rich media advertising, sponsorship of content offerings, and local and classified advertising. Through its broad network, AOL is able to offer content to a large user base. The AOL brand lost its spark several years ago but with recent restructuring, is picking up steam once again. As an increasing number of consumers look for entertainment and information online, companies like AOL stand to see rising profits.
5 Best US Stocks To Watch Right Now: OraSure Technologies Inc.(OSUR)
OraSure Technologies, Inc. develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States and internationally. It also manufactures and sells medical devices used for the removal of benign skin lesions by cryosurgery or freezing. The company offers OraQuick ADVANCE HIV-1/2, a point-of-care qualitative test for antibodies to the human immunodeficiency virus type 1 and type 2; OraQuick HCV, a point-of-care qualitative test for antibodies to the hepatitis C virus; OraSure QuickFlu Rapid Flu A&B Test, a point-of-care qualitative test for antibodies to influenza Types A and B, including H1N1 infections; OraSure, an oral fluid collection device for the detection of antibodies to HIV-1 in an oral fluid sample in a laboratory setting; and Intercept, an oral fluid collection device for oral fluid drugs of abuse testing in a laboratory setting. In addition, it provides MICRO-PLATE DOA Assays that are used to detect the drugs in an oral fluid sample collected with intercept device; cryosurgical freezing systems for the removal of warts and other benign skin lesions; and cryosurgical systems for the removal of common and plantar warts. Further, OraSure Technologies sells immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot HIV-1 confirmatory test for confirming positive HIV-1 test results obtained from the use of OraSure collection device; and Q.E.D., a point-of-care saliva alcohol test. The company sells its products through direct sales, strategic collaborations, and distributors to clinical laboratories, hospitals, clinics, community-based and other public health organizations, distributors, government agencies, physicians? offices, and commercial and industrial entities. It has collaboration agreement with Merck & Co. Inc. OraSure Technologies, Inc. was founded in 1979 and is based in Beth lehem, Pennsylvania.
Advisors' Opinion:- [By Seth Jayson]
OraSure Technologies (Nasdaq: OSUR ) reported earnings on May 8. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), OraSure Technologies beat slightly on revenues and met expectations on earnings per share. - [By Sam Collins]
OraSure Technologies (OSUR) — This small-cap company develops, manufactures and markets oral fluid diagnostic products and specimen collection devices using its proprietary oral fluid technologies.
- [By Keith Speights]
Progress has also been made on the diagnostic front. The FDA approved OraSure Technologies' (NASDAQ: OSUR ) OraQuick home HIV test in July 2012. OraQuick allows an individual to use a mouth swab and find out the results within 40 minutes. The test hasn't exactly leaped off store shelves as of yet, though. OraSure reported only $1.5 million in gross sales for the OraQuick home test during the most recent quarter.
Top 5 Rising Companies To Own For 2014: Merrimack Pharmaceuticals Inc (MACK)
Merrimack Pharmaceuticals, Inc., incorporated in 1993, is a biopharmaceutical company discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. The Company�� product candidates include MM-398, MM-121, MM-111, MM-302 and MM-151. As of June 31, 2011, the Company owned approximately 74% interest of Silver Creek.
The Company�� Network biology is an interdisciplinary approach to drug discovery and development that enables the Company to build functional and predictive computational models of biological systems based on quantitative, kinetic, multiplexed biological data. The Company provides its scientists with insights into how the complex molecular interactions that occur within cell signaling pathways, or networks, regulate cell decisions and how dysfunction within these networks leads to disease. The Company applies network biology throughout the research and development process, including for target identification, lead compound design and optimization, diagnostic discovery, in vitro and in vivo predictive development and the design of clinical trial protocols.
MM-398
MM-398 is a stable nanotherapeutic encapsulation, or enclosed sphere carrying an active drug, of the marketed chemotherapy drug irinotecan. MM-398 achieved its primary efficacy endpoints in Phase 2 clinical trials in pancreatic and gastric cancer. In an open label, single arm Phase 2 clinical trial of MM-398 as a monotherapy in 40 metastatic pancreatic cancer patients who had previously failed treatment with gemcitabine, patients treated with MM-398 achieved median overall survival of 22.4 weeks. Additionally, 20% of the patients in this Phase 2 trial survived for more than one year, and the Company observed a disease control rate, meaning patients exhibited stable disease or partial or complete response to treatment, of 47.5% at six weeks.
The Company focuses on initiati! ng a Phase 3 clinical trial of MM-398 for the treatment of patients with metastatic pancreatic cancer who have previously failed treatment with gemcitabine. The trial is expected to enroll approximately 250 patients and is designed to compare the efficacy of MM-398 as a monotherapy against the combination of the chemotherapy drugs fluorouracil, or 5-FU, and leucovorin. There are multiple ongoing Phase 1 and Phase 2 clinical trials of MM-398. In July 2011, the United States Food and Drug Administration (FDA) granted MM-398 orphan drug designation for the treatment of pancreatic cancer.
MM-121
MM-121 is a fully human monoclonal antibody that targets ErbB3, a cell surface receptor, or protein attached to the cell membrane that mediates communication inside and outside the cell, that the Company�� network biology approach identified as a target in a range of cancers. A monoclonal antibody is a type of protein normally produced by cells of the immune system that binds to just one epitope, or chemical structure, on a protein or other structure. MM-121 is designed to inhibit cancer growth directly, restore sensitivity to drugs to which a tumor has become resistant and delay the development of resistance of a tumor to other agents. In collaboration with Sanofi, the Company focuses on testing MM-121 in combination with both chemotherapies and other targeted agents across a range of spectrum of solid tumors, including lung, breast and ovarian cancers. The Company partnered MM-121 with Sanofi after it initiated Phase 1 clinical development of the product candidate.
MM-111
MM-111 is a bispecific antibody designed to target cancer cells that are characterized by overexpression of the ErbB2 cell surface receptor, also referred to as HER2. A bispecific antibody is a type of antibody that is able to bind simultaneously to two distinct proteins or epitopes. The Company�� network biology approach identified that ligand-induced signaling through the complex of ErbB2 ! (HER2) an! d ErbB3 is a promoter of tumor growth and survival than previously appreciated.
MM-302
MM-302 is a nanotherapeutic encapsulation of doxorubicin with attached antibodies that are designed to target MM-302 to cells that over express the ErbB2 (HER2) receptor. The Company is conducting a Phase 1 clinical trial of MM-302 in patients with advanced ErbB2 (HER2) positive breast cancer.
MM-151
MM-151 is an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor (EGFR). EGFR is also known as ErbB1. An oligoclonal therapeutic is a mixture of two or more distinct monoclonal antibodies. The Company has designed MM-151 to block signal amplification that occurs within the ErbB cell signaling network. The Company has submitted an investigational new drug application (IND), to the FDA for MM-151 in July 2011.
Advisors' Opinion:- [By Keith Speights]
Not so merry
Merrimack Pharmaceuticals (NASDAQ: MACK ) shareholders have had reason to party since early May, with the stock surging more than 60%. The merriment came to a stop this week, though, as shares tanked by 27%. - [By Monica Gerson]
Merrimack Pharmaceuticals (NASDAQ: MACK) dipped 15.38% to $2.86 after the company reported that Phase 2 study Of MM-121 missed primary endpoint.
IAC/InterActiveCorp (NASDAQ: IACI) shares fell 14.51% to $49.50 in the pre-market trading after the company reported downbeat Q3 revenue.
- [By John Udovich]
One way or the other, Merrimack Pharmaceuticals Inc (NASDAQ: MACK), Covidien plc (NYSE: COV), NeoGenomics, Inc (NASDAQ: NEO) and�CollabRx Inc (NASDAQ: CLRX) are targeting Barrett's Esophagus�or�esophageal cancer�(the former often leads to the latter) ��a form of cancer that may not be on the top of your list of cancers but is nevertheless on the rise. Approximately 3 million Americans suffer from Barrett's Esophagus, �a condition that�develops as a result of chronic injury from gastroesophageal reflux disease (GERD) where the�normal esophageal lining is replaced with abnormal cells (known as Barrett�� tissue), putting patients at greater risk of developing cancer of the esophagus. And although less than 1% of these patients develop cancer each year, esophageal carcinoma is frequently not detected until later stages, at which point therapy options are limited, extremely invasive, and often ineffective.�This means that�early detection is important�along with�regular surveillance is recommended.�
- [By Eric Volkman]
Merrimack Pharmaceuticals (NASDAQ: MACK ) is gearing up for a double dose of fund-raising. The company announced that it will concurrently float both a common stock and a convertible notes issue in a public offering. In the former, Merrimack will offer $50 million worth of shares, while the latter will take the form of $75 million in senior notes maturing in 2020. Additionally, the company expects that it will grant its underwriters a 30-day purchase option for up to an additional $7.5 million worth of common shares and $11.25 million of the convertible notes.
Top 5 Rising Companies To Own For 2014: Golub Capital BDC Inc (GBDC)
Golub Capital BDC, Inc. (Golub Capital BDC), incorporated on November 9, 2009, is an externally managed, closed-end, non-diversified management investment company. The Company's investment objective is to generate current income and capital appreciation by investing primarily in senior secured, one stop, second lien, subordinated loans of, and warrants and minority equity securities in, United States middle market companies. The Company seeks to create a diverse portfolio that includes senior secured, one stop, second lien and subordinated loans and warrants and minority equity securities by primarily investing in the securities of United States middle market companies. The Company's investment activities are managed by the Company's investment adviser, GC Advisors LLC (GC Advisors).
The Company seeks to generate risk-adjusted net returns by assembling a diversified portfolio of investments across a broad range of industries and private equity investors. The Company seeks to create a diverse portfolio that includes senior secured, one stop, second lien and subordinated loans and warrants and minority equity securities by primarily investing on average, in the securities of United States middle market companies. The Company primarily targets United States middle markets companies controlled by private equity investors that require capital for growth, acquisitions, recapitalizations, refinancings and leveraged buyouts. The Company may also make opportunistic loans to independently owned and publicly held middle market companies. The Company focuses on senior secured loans and one stops investments, given the principal protection from the first lien security interest associated with such loans.
Senior Secured Loans
The Company structures these investments as senior secured loans. The Company obtains security interests in the assets of the portfolio company that serve as collateral in support of the repayment of such loans. This collateral may take the form of! first-priority liens on the assets of the portfolio company borrower. The Company's senior secured loans may provide for moderate loan amortization in the early years of the loan, with the majority of the amortization deferred until loan maturity.
One Stop Loans
The Company structures its one stop loans as senior secured loans. The Company obtains security interests in the assets of the portfolio company that serve as collateral in support of the repayment of these loans. This collateral may take the form of first-priority liens on the assets of the portfolio company. One stop loans typically provide for moderate loan amortization in the initial years of the facility, with the majority of the amortization deferred until loan maturity. One stop loans generally allow the borrower to make a lump sum payment of principal at the end of the loan term, and there is a risk of loss if the borrower is unable to pay the lump sum or refinance the amount owed at maturity.
Second Lien Loans
The Company structures these investments as junior, secured loans. The Company obtains security interests in the assets of the portfolio company that serve as collateral in support of the repayment of such loans. This collateral may take the form of second priority liens on the assets of a portfolio company. Second lien loans typically provide for moderate loan amortization in the initial years of the facility, with the majority of the amortization deferred until loan maturity.
Subordinated Loans
1The Company structures these investments as unsecured, subordinated loans that provide for relatively high, fixed interests rates that provide the Company with interest income. These loans typically have interest-only payments (often representing a combination of cash pay and payment-in-kind, or PIK, interest) with amortization of principal deferred until loan maturity.
Advisors' Opinion:- [By Jordan Wathen]
Alas, Eliasek's second comment about making sure the assets are qualifying rules out a senior secured lending program -- a strategy employed by competitors including Golub Capital� (NASDAQ: GBDC ) and Ares Capital� (NASDAQ: ARCC ) .
- [By Monica Gerson]
Golub Capital BDC (NASDAQ: GBDC) dipped 2.88% to $17.89 in pre-market trading after the company announced a public offering of 3.5 million shares of its common stock.
Top 5 Rising Companies To Own For 2014: ECOtality Inc (ECTYQ)
Ecotality, Inc., incorporated in 1999, is a provider of electric transportation and storage technologies. The Company provides electric vehicle infrastructure products and solutions that are used in on-road, grid-connected vehicles (including plug-in hybrid electric vehicles (PHEV) and battery electric vehicles (BEV)), material handling and airport electric ground support applications. Through its main operating subsidiary, Electric Transportation Engineering Corporation (eTec), the Company�� primary product offering is the Minit-Charger line of advanced battery fast-charge systems that are designed for various motive applications. In addition to its electric transportation focus, Ecotality, Inc. is also involved in the development, manufacture, assembly and sale of specialty solar products, advanced battery systems, and hydrogen and fuel cell systems. Its subsidiaries and primary operating segments consist of eTec, Innergy Power Corporation (Innergy), and ECOtality Stores (doing business as Fuel Cell Store). In addition, the Company has a wholly owned subsidiary in Mexico providing manufacturing services for it and a wholly owned subsidiary in Australia, ECOtality Australia Pty Ltd, to market and distribute battery charging equipment to support on-road electric vehicles, industrial equipment, and electric airport ground support equipment.
The Company�� products include energy engineering services (hydrogen, solar, battery, coal gasification and energy delivery infrastructure); eTec�� Minit-Charger fast-charge systems for material handling and airport ground support equipment; charging systems (Level 2 and 3) for on-road grid-connected electric vehicles; eTec Bridge Power Manager (BPM) systems; hydrogen internal combustion engine (HICE) vehicle conversions; industrial battery systems; solar panel production; specialty solar solutions; specialty thin-sealed lead battery products, and various solar products for consumer, emergency response programs and remote power systems. The Compan! y�� products also include third-party hydrogen and education related products, and EV Microclimate Program.
Electric Transportation Engineering Corporation
As the Company�� primary operating subsidiary, eTec is engaged in the research, development and testing of advanced transportation and energy systems, and is the exclusive provider of the Minit-Charger line of battery fast-charge systems and technologies. Specializing in alternative-fuel, hybrid and electric vehicles and infrastructures, eTec offers consulting, technical support and field services. The Minit-Charger brand is the result of a consolidation of the two fast-charging technologies: eTec SuperCharge and Edison Minit-Charger. In March 2008, all eTec fast-charging products, including the eTec SuperCharge product line, were consolidated under the eTec Minit-Charger brand.
eTec holds the exclusive contract for the United States Department of Energy�� (DoE) Advanced Vehicle Testing Activity (AVTA) program and has conducted more than six million miles of vehicle testing on more than 200 advanced fuel vehicles. The Company acquired eTec as an expansion platform for its core capability in battery technologies, fast charging systems, energy distribution infrastructure, and advanced vehicle technologies and testing, which includes electric vehicle (EV), hybrid electric vehicle (HEV), PHEV and hydrogen vehicle technologies. As of December 31, 2009, eTec had installed more than 5,100 charging stations for motive applications.
On August 5, 2009, eTec was selected by the DoE for a grant to undertake the deployment of EVs and charging infrastructure. On September 30, 2009, eTec accepted the grant. eTec, as the lead applicant for the proposal, partnered with Nissan North America to deploy EVs and the charging infrastructure to support them. The project will install electric vehicle charging infrastructure and deploy up to a total of 4,700 Nissan battery electric vehicles in strategic markets in fiv! e states:! Arizona, California, Oregon, Tennessee and Washington.
Innergy Power Systems
Innergy Power Systems is based in San Diego, California, with a manufacturing facility in Tijuana, Mexico. Innergy is a manufacturer of both renewable energy solar modules and thin-sealed rechargeable batteries, as its solar photovoltaic (PV) product line addresses the worldwide demand for solar energy products and off-grid power. Innergy�� fiberglass reinforced panel (FRP) solar modules are designed to meet a range of applications for emergency preparedness and recreation. Applications include logistics tracking, asset management systems, off-grid lighting, mobile communications, mobile computing, recreational vehicles, signaling devices and surveillance cameras. Innergy and the Company�� wholly owned subsidiary providing manufacturing services, Portable Energy De Mexico, S.A. DE C.V., provides the Company the ability to further expand its production, manufacturing and assembly capabilities for Innergy�� solar products and energy storage devices, as well as products of its other subsidiaries, including eTec�� Minit-Charger products.
ECOtality Stores (doing business as Fuel Cell Store)
ECOtality Stores is the Company�� wholly owned subsidiary and operates as its online retail division. Fuel Cell Store (www.fuelcellstore.com) is an e-commerce marketplace that offers consumers an array of fuel cell products from around the globe. Based in San Diego, California, and with international operations in Japan, Russia, Italy and Portugal, Fuel Cell Store develops, manufactures and sells a range of fuel cell products that includes fuel cell stacks, systems, component parts and educational materials. In addition to primary retail operations, Fuel Cell Store also offers consulting services for high schools, colleges and research institutes, and is available to host workshops, conferences and corporate events.
Hydrality
Hydrality is a reactor system t! hat store! s and delivers hydrogen on-demand using magnesium compounds and water. The EPC/Hydrality technology was initially developed in conjunction with National Aeronautics and Space Administration�� (NASA) Jet Propulsion Laboratory (JPL) and subsequently advanced by Arizona State University, Green Mountain Engineering and Airboss Aerospace, Inc. The Company initially sought to design and license a Hydrality system for use in motorized vehicles and industrial equipment, it has identified several additional applications for Hydrality that include stationary applications for remote power, back-up power systems, and large-scale industrial and utility use.
The Company competes with AeroVironment, Inc., Aker Wade Power Technologies LLC, Power Designers, LLC, and C&D Technologies, Inc., Better Place, Coulomb Technologies, AeroVironment, Inc., Aker Wade Power Technologies, LLC, Delta-Q Technologies, Elektromotive, BP Solar International Inc., Evergreen Solar, Inc., First Solar Inc., Kyocera Corporation, Mitsubishi Electric Corporation, Motech Industries Inc., Q-Cells AG, Sanyo Corporation, Sharp Corporation, SolarWorld AG, Suntech Power Holdings Co., Ltd., Airgas, Inc., Air Liquide, Air Products and Chemicals, Inc., Linde AG, Praxair Technology, Inc., Distributed Energy Systems Corporation, Hydrogenics Corporation, Statoil Hydro, Teledyne Energy Systems, Inc., Heliocentris Fuel Cells AG, Horizon Fuel Cell Technologies, Ltd., BCS Fuel Cells, Inc., Electrochem, Inc., Fuel Cell Scientific, LLC, GasHub Technology, JHT Power, H-Tech, Inc., Element-1 Power Systems and miniHYDROGEN.
Advisors' Opinion:- [By abirk]
Founded in 1883, Kroger, together with its subsidiaries, operates as a retailer in the United States. The company also manufactures and processes food for sale in its supermarkets. With a market cap of 22.72 billion, this Cincinnati, Ohio, based company is the seventh largest grocery retailer in the world and, along with Wal-Mart Stores, Inc. (WMT) and Costco Wholesale Corporation (COST), one of only three U.S. companies in the top ten. Extending well beyond its retail grocer core business, Kroger operates under nearly two dozen banners including: Kroger Real Estate, The Little Clinic, I-Wireless, Kroger Convenience Stores, Littman Jewelers, Fred Meyer Jewelers, Kroger Manufacturing, Kroger Pharmacies, and the recently-acquired Harris Teeter Supermarkets, Inc. (HTSI) (merger transaction between the two companies was completed on January 28, 2014). About half of the Kroger's supermarkets include gas stations. Further, partnering with Ecotality, Inc. (ECTYQ), Kroger has introduced electric car charging stations.
- [By Sean Williams]
Captain, I just don't have the infrastructure!
Without question, car companies are on a quest to create the perfect blend of performance, fuel-efficiency, and zero emissions. At the moment, only one company has done a good job of that, and its name is Tesla Motors. But looking at the big picture, the electric vehicles that Tesla produces make up just a fraction of the current automotive market. The real barrier to entry for any alternative modes of transportation is a lack of infrastructure, which is why I think the recent rally in ECOtality (NASDAQOTH: ECTYQ ) is unwarranted.
No comments:
Post a Comment